Context Therapeutics Inc.

CNTX

Healthcare|Biotechnology|US

$0.19

+0.01 (+2.98%)

DCF Value

$0.67

Tangible Book / Share

$0.40

Cash / Share

$0.45

About

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Stock Price

-81.9%(1Y)

-35.3%

-60.0%

-91.9%

YTD

-86.8%

-83.9%

-81.7%

-96.7%

Pipeline Summary

9 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Terminated: 3Recruiting: 2Completed: 2Withdrawn: 2

Active Trials (2)

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT06515613Platinum-resistant Ovarian Cancer

Phase 1Recruiting

Enrollment: 156 participants

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

NCT07545122Triple Negative Breast Cancer (TNBC)

Phase 1Recruiting

Enrollment: 162 participants

Key Facts

Market Cap$17.8M

Employees15 (+25% YoY)

CEOMartin A. Lehr

IPO DateOct 20, 2021

Beta1.77

52-Week Range$0.18 – $3.62

Avg Volume1,784,839

ExchangeNASDAQ

Websitecontexttherapeutics.com

Ownership

Float69.4%

Shares Outstanding91.9M